LUND, S.E., April 29, 2025 – TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), is advancing the next phase of its strategic growth journey under CEO Markus Granlund. Guided by its mission to empower partners and enrich lives, TFS is expanding global capabilities, embracing digital transformation, and strengthening operational agility to drive meaningful impact across the clinical research landscape. The organization remains committed to supporting partners in advancing treatments that promote health and well-being worldwide, delivering flexible, high-quality solutions that meet the demands of an evolving industry.
Building on nearly three decades of clinical research expertise, TFS HealthScience is reinforcing its reputation as a trusted mid-sized CRO partner by expanding global trial delivery capabilities, advancing next-generation digital platforms, and sharpening therapeutic focus to better meet the evolving needs of pharmaceutical and biotech sponsors. These strategic enhancements strengthen operational agility and customer alignment, enabling TFS to deliver greater flexibility, speed, and therapeutic insight. Through these efforts, TFS is helping sponsors navigate increasingly complex development environments while accelerating access to innovative therapies for patients worldwide.
“TFS is embracing change as an opportunity to sharpen our focus and elevate our impact,” said Markus Granlund, CEO of TFS. “With a strong foundation in scientific and operational excellence, we remain committed to evolving alongside our customers—adapting to shifting market needs and continuing to deliver value where it matters most. As the industry advances, so does our dedication to meaningful outcomes—for sponsors, for patients, and for the future of clinical research.”
Under Granlund’s leadership, TFS has continued to expand its global footprint, growing its reach in key international markets, including the United States. The company’s established presence in the Research Triangle Park (RTP) life sciences hub—one of the largest biotech clusters in the world—was recently recognized with the 2025 Life Sciences Award from the Triangle Business Journal, affirming TFS’s rising leadership in the clinical research sector.
In parallel, TFS is reinforcing its internal foundations by investing in employee development, expanding leadership opportunities, and enhancing operational structures to foster greater therapeutic expertise and closer client alignment. By bringing greater flexibility and specialization to its therapeutic focus areas, TFS is enabling a more responsive, tailored approach that better supports the diverse needs of its global partners. These initiatives are fueling a culture of innovation, collaboration, and adaptability, ensuring TFS remains closely connected to the needs of its customers while delivering on its broader mission to advance health outcomes worldwide.
As TFS accelerates its strategic vision under new leadership, it remains driven by a singular focus: to empower partners with adaptable solutions, enable employees to lead innovation, and enrich lives globally through smarter clinical research.
About TFS HealthScience
TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With operations across 40 countries, TFS and its strategic partners provide tailored strategic resourcing solutions and clinical development services in specialized therapeutic areas, including dermatology, internal medicine, neuroscience, oncology, and ophthalmology. Dedicated to empowering partners and enriching lives, TFS offers flexible solutions that combine global reach with the agility and responsiveness of a mid-sized CRO.
For more information, visit www.tfscro.com.